<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494038</url>
  </required_header>
  <id_info>
    <org_study_id>P1078</org_study_id>
    <secondary_id>10732</secondary_id>
    <secondary_id>IMPAACT P1078</secondary_id>
    <nct_id>NCT01494038</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women</brief_title>
  <official_title>A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High Tuberculosis (TB) Incidence Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis (TB) is a leading cause of death among HIV-infected persons in low-income
      settings and can be a serious complication for HIV-infected pregnant women and their infants.
      Isoniazid (INH) preventive therapy (IPT) is effective in preventing TB infection in
      HIV-infected adults, but the safety of IPT in pregnant women is unknown. This study evaluated
      the safety of IPT among HIV-infected pregnant women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TB disease is the most common HIV-related opportunistic infection and is a leading cause of
      death among HIV-infected persons in low-income settings. When TB occurs during or soon after
      pregnancy, it can cause complications for the mother as well as infant TB or death. Infant TB
      is very difficult to diagnose, and up to half of infant TB cases are caused by maternal TB.
      It has been shown that treatment for active TB is safe and effective during pregnancy and
      that IPT is safe and effective in preventing TB infection in HIV-infected adults. However,
      the safety of IPT in HIV-infected pregnant women is not known, especially in regard to its
      combination with highly active retroviral therapy (HAART). This study evaluated the safety of
      immediate (antepartum, or before delivery) versus deferred (postpartum, or after delivery)
      IPT among HIV-infected pregnant women in high TB incidence settings.

      HIV-infected pregnant women were randomly assigned (1:1) to one of two arms: Arm A
      (immediate/antepartum INH) and Arm B (deferred/postpartum INH group). Women in both arms
      received oral prenatal multivitamins and pyridoxine (vitamin B6) once daily from study entry
      through Week 40 postpartum.

      Study visits for women occurred at screening, entry, every 4 weeks until labor and delivery,
      at labor and delivery, and every 4 weeks after delivery until 48 weeks postpartum. Visits
      consisted of giving a medical history and undergoing a physical exam and blood collection;
      all visits through the delivery visit also included an obstetrical exam. Presence of HIV
      infection was documented at screening and a tuberculin skin test (TST) was administered at
      the delivery visit and at the Week 44 postpartum visit. Study visits for infants occurred at
      birth and at several time points through Week 48. These visits included a medical history,
      physical exam, and blood collection. Intensive pharmacokinetic (PK) samples, that is, samples
      taken at many different time points within a 24-hour test period, were collected from a small
      subset of women, one test period at antepartum and one at postpartum. Sparse PK samples, that
      is, samples taken at fewer time points within the test period, were collected on all women,
      once each at antepartum and postpartum.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 19, 2014</start_date>
  <completion_date type="Actual">September 6, 2017</completion_date>
  <primary_completion_date type="Actual">September 6, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Rate of Combined Endpoint: Grade 3 or Higher Adverse Events (AEs) Related to Treatment, or AE Causing Discontinuation of Treatment</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>Incidence rate, calculated by Mantel-Haenszel (MH), weighted by gestational age strata 1) gestational age at entry less than 24 weeks or 2) gestational age at entry greater than or equal to 24 weeks. AE's include laboratory results, signs/symptoms, or diagnoses; graded as per Division of AIDS (DAIDS) or by protocol-defined hepatotoxicity measures. Related to treatment indicates possibly, probably, or definitely related to INH or Placebo for INH as judged by Independent Endpoint Review Committee. Discontinuation refers to permanent discontinuation of study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Mothers With a Fetal Death</measure>
    <time_frame>Measured from study entry through end of pregnancy</time_frame>
    <description>Fetal deaths include both stillbirths and spontaneous abortions; in case of a multiple birth, mothers who had at least one fetal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Mothers With a Fetus Small for Gestational Age</measure>
    <time_frame>Measured at delivery</time_frame>
    <description>Small for gestational age was determined by physician at site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Mothers With an Infant Born Prematurely</measure>
    <time_frame>Measured at delivery</time_frame>
    <description>Premature birth is defined as gestational age of &lt; 37 weeks at delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Mothers With a Low Birth-weight Infant</measure>
    <time_frame>Measured on day of birth</time_frame>
    <description>Low birth weight is defined as weight &lt; 2500 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Mothers With an Infant With a Congenital Anomaly</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>Includes congenital anomalies meeting the Metropolitan Atlanta Congenital Defects Program criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Mothers With an Adverse Pregnancy Outcome: Spontaneous Abortion, Stillbirth, Premature Birth, Low Birth Weight, or Congenital Anomaly</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>In case of a multiple birth, mothers who had at least one adverse pregnancy outcome. Spontaneous abortion is intra-uterine fetal death prior to 20 weeks of gestational age; stillbirth, the same, &gt;= 20 weeks; preterm delivery, &lt; 37 weeks of gestational age; low birth weight, &lt; 2,500 grams, and congenital anomalies meeting the Metropolitan Atlanta Congenital Defects Program criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Grade 3 or Higher Clinical or Laboratory AE</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>Laboratory, sign/symptom, or diagnoses graded as 3 or higher by DAIDS criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Grade 3 or Higher Clinical or Laboratory AE Related to Treatment</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>As before, but AE is judged to be possibly, probably, or definitely related to INH or Placebo for INH, by clinic medical staff</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants Which Are HIV-infected</measure>
    <time_frame>Measured from study entry through study Week 44</time_frame>
    <description>HIV infection determined during follow-up period. Infection at birth or during breastfeeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants Hospitalized</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>Hospitalization due to reasons other than birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of TB Infection Among Mothers</measure>
    <time_frame>Measured from study entry to Week 48 after birth</time_frame>
    <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB infection, as judged by Secondary Endpoint Review Committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Tuberculosis (TB) Among Infants</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB, or congenital TB as defined using the Cantwell criteria (see reference), judged by the Secondary Endpoint Review Committee. Includes an infant death due to unknown cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Infant Death</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>Incidence rate was calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Maternal Deaths</measure>
    <time_frame>Measured from study entry through Week 48 postpartum</time_frame>
    <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Combined Endpoints: Maternal TB or Maternal Death</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Combined Endpoints: Infant TB or Infant Death</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Combined Endpoints: Maternal TB, Maternal Death, Infant TB, or Infant Death</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Combined Endpoint, Antepartum: Grade 3 or Higher AE Related to Treatment, or Discontinuation of Treatment Due to AE</measure>
    <time_frame>Measured from study entry through end of pregnancy</time_frame>
    <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Combined Endpoint, up to 12 Weeks Postpartum: Grade 3 or Higher AE Related to Treatment, or Discontinuation of Treatment Due to AE</measure>
    <time_frame>Measured from study entry through 12 weeks after birth</time_frame>
    <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate, Antepartum, of Grade 3 or Higher AE</measure>
    <time_frame>Measured from study entry through end of pregnancy</time_frame>
    <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate, up to 12 Weeks Postpartum, of Grade 3 or Higher AE</measure>
    <time_frame>Measured from study entry through 12 weeks postpartum</time_frame>
    <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate, Antepartum, of Hepatotoxicity, Defined by Protocol-specific Definition of Hepatotoxicity, Related to Treatment</measure>
    <time_frame>Measured from study entry through delivery</time_frame>
    <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. Protocol-specific definition of hepatotoxicity: Any one of the following: 1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 5 times the upper limit of normal (ULN), where ULN is specified by the clinic physician; 2) Total bilirubin &gt; 3 X ULN; 3) ALT greater than 3 X ULN and total bilirubin greater than 2 X ULN; or 4) ALT &gt; 3 X ULN and persistent symptomatic clinical hepatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate, to 12 Weeks Postpartum, of Hepatotoxicity, Protocol-specific Definition, Related to Treatment</measure>
    <time_frame>Measured from study entry through 12 weeks postpartum</time_frame>
    <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate, Antepartum, of Hepatotoxicity, Protocol-specific Definition, Any Cause</measure>
    <time_frame>Measured from study entry through delivery</time_frame>
    <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate, to 12 Weeks Postpartum, of Hepatotoxicity, Protocol-specific Definition, Any Cause</measure>
    <time_frame>Measured from study entry through 12 weeks postpartum</time_frame>
    <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate, Antepartum, of Hepatotoxicity, Defined by DAIDS, Related to Treatment</measure>
    <time_frame>Measured from study entry through delivery</time_frame>
    <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Hepatotoxicity definition as defined by DAIDS AE grading criteria 1.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate, up to 12 Weeks Postpartum, of Hepatotoxicity, Defined by DAIDS, Related to Treatment</measure>
    <time_frame>Measured from study start through 12 weeks postpartum</time_frame>
    <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate, Antepartum, of Hepatotoxicity, Defined by DAIDS, Any Cause</measure>
    <time_frame>Measured from study entry through delivery</time_frame>
    <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate, up to 12 Weeks Postpartum, of Hepatotoxicity, Defined by DAIDS, Any Cause</measure>
    <time_frame>Measured from study start through 12 weeks postpartum</time_frame>
    <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Mothers With Tuberculosis Resistant to INH</measure>
    <time_frame>Measured from study entry through Week 48 postpartum</time_frame>
    <description>Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of mothers who develop culture-confirmed TB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Tuberculosis Resistant to INH</measure>
    <time_frame>Measured from study entry through Week 48 after birth</time_frame>
    <description>Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of infants who develop culture-confirmed TB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Adjusted Mean of Area Under the Curve of Plasma Concentration Versus Time (AUC24h), for INH</measure>
    <time_frame>Measured at antepartum (third trimester and &gt;= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.</time_frame>
    <description>Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Adjusted Mean of Area Under the Curve (AUC24h), for EFV</measure>
    <time_frame>Measured at antepartum (third trimester and &gt;= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.</time_frame>
    <description>Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agreement Between Interferon-gamma Release Assay (IGRA) TB Test and Tuberculin Skin Test (TST) Results, Women at Delivery</measure>
    <time_frame>Measured at delivery</time_frame>
    <description>IGRA done by Quantiferon Gold Test (QGIT). For women, TST is considered positive if greater than or equal to 5 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agreement Between IGRA and TST TB Test Results, Infant</measure>
    <time_frame>Measured at week 44 after birth</time_frame>
    <description>The TST result was positive if greater than or equal to 10 mm in HIV-negative infants, or greater than or equal to 5 mm in HIV-positive infants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Agreement Between IGRA and TST TB Tests, Women at 44 Weeks Postpartum</measure>
    <time_frame>Measured at Week 44 postpartum</time_frame>
    <description>IGRA done by Quantiferon Gold Test (QGIT). For women, TST is considered positive if greater than or equal to 5 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Women by Level of Adherence to Prescribed Regimen, as Assessed by Self-report</measure>
    <time_frame>Adherence reported every 4 weeks during active treatment; study entry through week 28 for Arm A, week 12 postpartum through week 40 postpartum for Arm B</time_frame>
    <description>Adherence is the percentage of expected doses taken during the 28 week active treatment period, categorized as poor (&lt;60%), reasonable (&gt;= 60%, &lt;80%), good (&gt;=80%, &lt;90%), or excellent (&gt;= 90%). Measured by participant's self-report of doses taken within the last 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Women by Level of Adherence to Prescribed Regimen, as Assessed by Pill Count</measure>
    <time_frame>Adherence reported every 4 weeks during active treatment; study entry through week 28 for Arm A, week 12 postpartum through week 40 postpartum for Arm B</time_frame>
    <description>Adherence is the percentage of expected doses taken during the 28 week active treatment period. Pill count: participants returned their prescription pill containers, and the remaining (unused) pills were counted.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">956</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Arm A (Immediate INH Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Deferred INH Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid (INH)</intervention_name>
    <description>300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)</description>
    <arm_group_label>Arm A (Immediate INH Treatment)</arm_group_label>
    <arm_group_label>Arm B (Deferred INH Treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for isoniazid (INH)</intervention_name>
    <description>Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)</description>
    <arm_group_label>Arm A (Immediate INH Treatment)</arm_group_label>
    <arm_group_label>Arm B (Deferred INH Treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection, defined as positive results from two samples collected at
             different time points. All samples tested must be whole blood, serum, or plasma. More
             information on this criterion can be found in the protocol.

          -  Documented HIV treatment, according to World Health Organization (WHO) guidelines, for
             prevention of mother-to-child transmission (PMTCT) and standard of care for HIV
             infection

          -  Pregnant females age 18 years or older

          -  Pregnant females between greater than or equal to 13 and less than 18 who are able and
             willing to provide signed informed consent under local law or pregnant females unable
             to consent under local law whose parents/legal guardians provide consent or &quot;minimum
             age of consent according to locally applicable laws or regulations&quot;

          -  Pregnancy gestational age confirmed by best available method at site to be greater
             than or equal to 14 weeks through less than or equal to 34 weeks (34 weeks, 6 days)

          -  Weight greater than or equal to 35 kg at screening

          -  The following laboratory values obtained within 30 days prior to study entry:

               -  Absolute neutrophil count (ANC) greater than or equal to 750 cells/mm^3

               -  Hemoglobin greater than or equal to 7.5 g/dL

               -  Platelet count greater than or equal to 50,000/mm^3

               -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT),
                  alkaline phosphatase (ALT)/serum glutamic pyruvic transaminase (SGPT), and total
                  bilirubin less than or equal to 1.25 times the upper limit of normal (ULN).
                  (Note: If participant is taking atazanavir, direct bilirubin may be used to
                  determine eligibility.)

          -  Intent to remain in current geographical area of residence for the duration of the
             study

        Exclusion Criteria:

          -  Any woman with a positive TB symptom screen per WHO guidelines, including any one or
             more of the following: any cough, fever, self-reported weight loss, or night sweats.
             Note: If a potential participant is found to be negative for TB upon further testing,
             the participant may be rescreened for the study.

          -  Any positive acid-fast bacillus (AFB) smear, Xpert, or any other rapid TB screening
             test or culture from any site within the past 12 weeks, or chest radiograph (x-ray)
             with findings suggestive of active TB, or clinician suspects active TB

          -  Known exposure to AFB smear-positive active TB case within past 12 weeks prior to
             study entry

          -  Reported INH exposure (more than 30 days) in the past year prior to study entry

          -  Receipt of any TB or atypical mycobacteria therapy for more than 30 days in the past
             year

          -  Evidence of acute hepatitis, such as jaundice, dark urine (not concentrated urine),
             and/or acholic stools sustained for more than 3 days within 90 days prior to entry.
             More information on this criterion can be found in the protocol.

          -  Grade 1 or higher peripheral neuropathy. More information on this criterion can be
             found in the protocol.

          -  History of acute systemic adverse reaction or allergy to INH

          -  Known current heavy alcohol use (more than 2 drinks per week) or alcohol exposure
             that, in the investigator's opinion, would compromise participation and the outcome of
             this study

          -  Presence of new AIDS-defining opportunistic infection that has been treated less than
             30 days prior to study entry

          -  Receipt of an investigational agent or chemotherapy for active malignancy within 30
             days prior to study entry

          -  Any clinically significant diseases (other than HIV infection) or clinically
             significant findings during the screening medical history or physical examination
             that, in the investigator's opinion, would compromise participation and the outcome of
             this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amita Gupta, MD, MHS</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gaborone CRS</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molepolole CRS</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS</name>
      <address>
        <city>Port-au-Prince</city>
        <zip>HT-6110</zip>
        <country>Haiti</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Byramjee Jeejeebhoy Medical College (BJMC) CRS</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto IMPAACT CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape Province</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fam-Cru Crs</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape Province</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Christian Medical Centre (KCMC)</name>
      <address>
        <city>Moshi</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MU-JHU Research Collaboration (MUJHU CARE LTD) CRS</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seke North CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's CRS</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harare Family Care CRS</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>Haiti</country>
    <country>India</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Thailand</country>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <link>
    <url>http://rsc.tech-res.com/docs/default-source/safety/manual_for_expedited_reporting_aes_to_daids_v2.pdf?sfvrsn=12</url>
    <description>Manual for Expedited Reporting of Adverse Events to Division of AIDS (DAIDS), Version 2.0, January 2010</description>
  </link>
  <link>
    <url>http://rsc.tech-res.com/docs/default-source/safety/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf?sfvrsn=6</url>
    <description>Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004 (Clarification, August 2009)</description>
  </link>
  <link>
    <url>https://www.cdc.gov/ncbddd/birthdefects/macdp.html</url>
    <description>Metropolitan Atlanta Congenital Defects Program (MACDP)</description>
  </link>
  <reference>
    <citation>Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000171. doi: 10.1002/14651858.CD000171.pub3. Review.</citation>
    <PMID>20091503</PMID>
  </reference>
  <reference>
    <citation>Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H, Lombard CJ. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007 Jan 20;334(7585):136. Epub 2006 Nov 3.</citation>
    <PMID>17085459</PMID>
  </reference>
  <reference>
    <citation>Cantwell MF, Snider DE Jr, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA. 1994 Aug 17;272(7):535-9.</citation>
    <PMID>8046808</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <results_first_submitted>September 6, 2018</results_first_submitted>
  <results_first_submitted_qc>October 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2018</results_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT01494038/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 28, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT01494038/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HIV-infected pregnant women and their infants, gestational age greater than 14 but less than 34 weeks, who reside in a high TB prevalence area. Recruited at participating medical clinics in those areas, a total of 13 sites in Haiti, India, Thailand, and in 5 countries in central and southern Africa. Recruitment from August 2014 to April 2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Immediate INH Treatment)</title>
          <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Deferred INH Treatment)</title>
          <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="477"/>
                <participants group_id="P2" count="479"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
                <participants group_id="P2" count="396"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not able to get to clinic</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not willing to adhere to reqs</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All women in study.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Immediate INH Treatment)</title>
          <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
        </group>
        <group group_id="B2">
          <title>Arm B (Deferred INH Treatment)</title>
          <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum (Arm B)
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit (Arm B)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="477"/>
            <count group_id="B2" value="479"/>
            <count group_id="B3" value="956"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="25" upper_limit="33"/>
                    <measurement group_id="B2" value="29" lower_limit="24" upper_limit="33"/>
                    <measurement group_id="B3" value="29" lower_limit="24" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="477"/>
                    <measurement group_id="B2" value="479"/>
                    <measurement group_id="B3" value="956"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="445"/>
                    <measurement group_id="B2" value="444"/>
                    <measurement group_id="B3" value="889"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Haiti</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Botswana</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tanzania</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zimbabwe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at entry</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>14 - &lt;24 weeks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="321"/>
                  </measurement_list>
                </category>
                <category>
                  <title>24 - 34 weeks</title>
                  <measurement_list>
                    <measurement group_id="B1" value="316"/>
                    <measurement group_id="B2" value="319"/>
                    <measurement group_id="B3" value="635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Count</title>
          <population>N=4 participants did not have baseline CD4 result available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="475"/>
                    <count group_id="B2" value="477"/>
                    <count group_id="B3" value="952"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt; 350 cells/mm^3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
                <category>
                  <title>350 - &lt;500 cells/mm^3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
                <category>
                  <title>500 - &lt;650 cells/mm^3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 650 cells/mm^3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Efavirenz-containing anti-retroviral (ARV) regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="477"/>
                    <count group_id="B2" value="479"/>
                    <count group_id="B3" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="409"/>
                    <measurement group_id="B3" value="814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tuberculosis (TB) test result by Interferon-Gamma Release Assay (IGRA)</title>
          <population>All enrolled participants with IGRA results available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="470"/>
                    <count group_id="B2" value="472"/>
                    <count group_id="B3" value="942"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="283"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="301"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="598"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indeterminate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Combined Endpoint: Grade 3 or Higher Adverse Events (AEs) Related to Treatment, or AE Causing Discontinuation of Treatment</title>
        <description>Incidence rate, calculated by Mantel-Haenszel (MH), weighted by gestational age strata 1) gestational age at entry less than 24 weeks or 2) gestational age at entry greater than or equal to 24 weeks. AE's include laboratory results, signs/symptoms, or diagnoses; graded as per Division of AIDS (DAIDS) or by protocol-defined hepatotoxicity measures. Related to treatment indicates possibly, probably, or definitely related to INH or Placebo for INH as judged by Independent Endpoint Review Committee. Discontinuation refers to permanent discontinuation of study treatment.</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>All women enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Combined Endpoint: Grade 3 or Higher Adverse Events (AEs) Related to Treatment, or AE Causing Discontinuation of Treatment</title>
          <description>Incidence rate, calculated by Mantel-Haenszel (MH), weighted by gestational age strata 1) gestational age at entry less than 24 weeks or 2) gestational age at entry greater than or equal to 24 weeks. AE's include laboratory results, signs/symptoms, or diagnoses; graded as per Division of AIDS (DAIDS) or by protocol-defined hepatotoxicity measures. Related to treatment indicates possibly, probably, or definitely related to INH or Placebo for INH as judged by Independent Endpoint Review Committee. Discontinuation refers to permanent discontinuation of study treatment.</description>
          <population>All women enrolled.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.03"/>
                    <measurement group_id="O2" value="14.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Calculate the difference between the immediate arm incidence rate and the deferred arm incidence rate; if the upper bound of the 95% confidence interval is lower than a 5% difference in incidence rates, non-inferiority will be considered to be proven.</non_inferiority_desc>
            <param_type>Incidence rate difference</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.77</ci_lower_limit>
            <ci_upper_limit>4.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Mothers With a Fetal Death</title>
        <description>Fetal deaths include both stillbirths and spontaneous abortions; in case of a multiple birth, mothers who had at least one fetal death</description>
        <time_frame>Measured from study entry through end of pregnancy</time_frame>
        <population>Mothers who had at least one live birth, stillbirth, or spontaneous abortion. One participant with outcome of induced abortion not included</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Mothers With a Fetal Death</title>
          <description>Fetal deaths include both stillbirths and spontaneous abortions; in case of a multiple birth, mothers who had at least one fetal death</description>
          <population>Mothers who had at least one live birth, stillbirth, or spontaneous abortion. One participant with outcome of induced abortion not included</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.093</p_value>
            <method>Fisher Exact</method>
            <method_desc>mid-P adjustment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Mothers With a Fetus Small for Gestational Age</title>
        <description>Small for gestational age was determined by physician at site</description>
        <time_frame>Measured at delivery</time_frame>
        <population>Measurement of small-for-gestational-age was deemed to be unreliable. Analysis not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Mothers With a Fetus Small for Gestational Age</title>
          <description>Small for gestational age was determined by physician at site</description>
          <population>Measurement of small-for-gestational-age was deemed to be unreliable. Analysis not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Mothers With an Infant Born Prematurely</title>
        <description>Premature birth is defined as gestational age of &lt; 37 weeks at delivery.</description>
        <time_frame>Measured at delivery</time_frame>
        <population>Mothers who had at least one live birth</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Mothers With an Infant Born Prematurely</title>
          <description>Premature birth is defined as gestational age of &lt; 37 weeks at delivery.</description>
          <population>Mothers who had at least one live birth</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="442"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.288</p_value>
            <method>Fisher Exact</method>
            <method_desc>mid-P adjustment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Mothers With a Low Birth-weight Infant</title>
        <description>Low birth weight is defined as weight &lt; 2500 mg</description>
        <time_frame>Measured on day of birth</time_frame>
        <population>Mothers who had at least one live birth available to be weighed at time of delivery</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Mothers With a Low Birth-weight Infant</title>
          <description>Low birth weight is defined as weight &lt; 2500 mg</description>
          <population>Mothers who had at least one live birth available to be weighed at time of delivery</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
                <count group_id="O2" value="446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="368"/>
                    <measurement group_id="O2" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.073</p_value>
            <method>Fisher Exact</method>
            <method_desc>mid-P adjustment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Mothers With an Infant With a Congenital Anomaly</title>
        <description>Includes congenital anomalies meeting the Metropolitan Atlanta Congenital Defects Program criteria.</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>Mothers who had at least one live birth able to be assessed between birth and 48 weeks after birth</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Mothers With an Infant With a Congenital Anomaly</title>
          <description>Includes congenital anomalies meeting the Metropolitan Atlanta Congenital Defects Program criteria.</description>
          <population>Mothers who had at least one live birth able to be assessed between birth and 48 weeks after birth</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="430"/>
                    <measurement group_id="O2" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.264</p_value>
            <method>Fisher Exact</method>
            <method_desc>mid-P adjustment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Mothers With an Adverse Pregnancy Outcome: Spontaneous Abortion, Stillbirth, Premature Birth, Low Birth Weight, or Congenital Anomaly</title>
        <description>In case of a multiple birth, mothers who had at least one adverse pregnancy outcome. Spontaneous abortion is intra-uterine fetal death prior to 20 weeks of gestational age; stillbirth, the same, &gt;= 20 weeks; preterm delivery, &lt; 37 weeks of gestational age; low birth weight, &lt; 2,500 grams, and congenital anomalies meeting the Metropolitan Atlanta Congenital Defects Program criteria.</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>Mothers who had at least one live birth, stillbirth, or spontaneous abortion; participant with induced abortion is omitted, and whose babies were available for examination after birth (if born alive)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Mothers With an Adverse Pregnancy Outcome: Spontaneous Abortion, Stillbirth, Premature Birth, Low Birth Weight, or Congenital Anomaly</title>
          <description>In case of a multiple birth, mothers who had at least one adverse pregnancy outcome. Spontaneous abortion is intra-uterine fetal death prior to 20 weeks of gestational age; stillbirth, the same, &gt;= 20 weeks; preterm delivery, &lt; 37 weeks of gestational age; low birth weight, &lt; 2,500 grams, and congenital anomalies meeting the Metropolitan Atlanta Congenital Defects Program criteria.</description>
          <population>Mothers who had at least one live birth, stillbirth, or spontaneous abortion; participant with induced abortion is omitted, and whose babies were available for examination after birth (if born alive)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="460"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="343"/>
                    <measurement group_id="O2" value="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Fisher Exact</method>
            <method_desc>Mid-P adjustment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Grade 3 or Higher Clinical or Laboratory AE</title>
        <description>Laboratory, sign/symptom, or diagnoses graded as 3 or higher by DAIDS criteria.</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>Infants born alive</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Grade 3 or Higher Clinical or Laboratory AE</title>
          <description>Laboratory, sign/symptom, or diagnoses graded as 3 or higher by DAIDS criteria.</description>
          <population>Infants born alive</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Grade 3 or Higher Clinical or Laboratory AE Related to Treatment</title>
        <description>As before, but AE is judged to be possibly, probably, or definitely related to INH or Placebo for INH, by clinic medical staff</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>Infants born alive</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Grade 3 or Higher Clinical or Laboratory AE Related to Treatment</title>
          <description>As before, but AE is judged to be possibly, probably, or definitely related to INH or Placebo for INH, by clinic medical staff</description>
          <population>Infants born alive</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants Which Are HIV-infected</title>
        <description>HIV infection determined during follow-up period. Infection at birth or during breastfeeding</description>
        <time_frame>Measured from study entry through study Week 44</time_frame>
        <population>Infants born alive</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants Which Are HIV-infected</title>
          <description>HIV infection determined during follow-up period. Infection at birth or during breastfeeding</description>
          <population>Infants born alive</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="436"/>
                    <measurement group_id="O2" value="451"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.279</p_value>
            <method>Fisher Exact</method>
            <method_desc>mid-P adjustment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants Hospitalized</title>
        <description>Hospitalization due to reasons other than birth</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>Infants born alive</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants Hospitalized</title>
          <description>Hospitalization due to reasons other than birth</description>
          <population>Infants born alive</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.893</p_value>
            <method>Fisher Exact</method>
            <method_desc>mid-P adjustment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of TB Infection Among Mothers</title>
        <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB infection, as judged by Secondary Endpoint Review Committee</description>
        <time_frame>Measured from study entry to Week 48 after birth</time_frame>
        <population>All participants enrolled without active TB at entry</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of TB Infection Among Mothers</title>
          <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB infection, as judged by Secondary Endpoint Review Committee</description>
          <population>All participants enrolled without active TB at entry</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60"/>
                    <measurement group_id="O2" value="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Tuberculosis (TB) Among Infants</title>
        <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB, or congenital TB as defined using the Cantwell criteria (see reference), judged by the Secondary Endpoint Review Committee. Includes an infant death due to unknown cause.</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>Live-born infants of enrolled women</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Tuberculosis (TB) Among Infants</title>
          <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB, or congenital TB as defined using the Cantwell criteria (see reference), judged by the Secondary Endpoint Review Committee. Includes an infant death due to unknown cause.</description>
          <population>Live-born infants of enrolled women</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54"/>
                    <measurement group_id="O2" value="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Infant Death</title>
        <description>Incidence rate was calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>Live-born infants of enrolled women</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Infant Death</title>
          <description>Incidence rate was calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>Live-born infants of enrolled women</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99"/>
                    <measurement group_id="O2" value="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>-1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.17</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Maternal Deaths</title>
        <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through Week 48 postpartum</time_frame>
        <population>All participants enrolled without active TB at entry</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Maternal Deaths</title>
          <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>All participants enrolled without active TB at entry</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40"/>
                    <measurement group_id="O2" value="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Combined Endpoints: Maternal TB or Maternal Death</title>
        <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>All participants enrolled without active TB at entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Combined Endpoints: Maternal TB or Maternal Death</title>
          <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>All participants enrolled without active TB at entry.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00"/>
                    <measurement group_id="O2" value="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.72</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Combined Endpoints: Infant TB or Infant Death</title>
        <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>Live-born infants of enrolled women</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Combined Endpoints: Infant TB or Infant Death</title>
          <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>Live-born infants of enrolled women</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99"/>
                    <measurement group_id="O2" value="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>-1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.48</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Combined Endpoints: Maternal TB, Maternal Death, Infant TB, or Infant Death</title>
        <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>Number of mother-infant pairs with at least one infant live birth and in which mother did not have active TB at entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Combined Endpoints: Maternal TB, Maternal Death, Infant TB, or Infant Death</title>
          <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>Number of mother-infant pairs with at least one infant live birth and in which mother did not have active TB at entry.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="442"/>
                <count group_id="O2" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42"/>
                    <measurement group_id="O2" value="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>-1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.86</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Combined Endpoint, Antepartum: Grade 3 or Higher AE Related to Treatment, or Discontinuation of Treatment Due to AE</title>
        <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata</description>
        <time_frame>Measured from study entry through end of pregnancy</time_frame>
        <population>All women enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Combined Endpoint, Antepartum: Grade 3 or Higher AE Related to Treatment, or Discontinuation of Treatment Due to AE</title>
          <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata</description>
          <population>All women enrolled.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.93"/>
                    <measurement group_id="O2" value="13.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>2.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.86</ci_lower_limit>
            <ci_upper_limit>12.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Combined Endpoint, up to 12 Weeks Postpartum: Grade 3 or Higher AE Related to Treatment, or Discontinuation of Treatment Due to AE</title>
        <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through 12 weeks after birth</time_frame>
        <population>All women enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Combined Endpoint, up to 12 Weeks Postpartum: Grade 3 or Higher AE Related to Treatment, or Discontinuation of Treatment Due to AE</title>
          <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>All women enrolled.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.98"/>
                    <measurement group_id="O2" value="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>6.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>13.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate, Antepartum, of Grade 3 or Higher AE</title>
        <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through end of pregnancy</time_frame>
        <population>All women enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate, Antepartum, of Grade 3 or Higher AE</title>
          <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>All women enrolled.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.36"/>
                    <measurement group_id="O2" value="50.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>5.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.7</ci_lower_limit>
            <ci_upper_limit>24.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate, up to 12 Weeks Postpartum, of Grade 3 or Higher AE</title>
        <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through 12 weeks postpartum</time_frame>
        <population>All women enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate, up to 12 Weeks Postpartum, of Grade 3 or Higher AE</title>
          <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>All women enrolled.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.48"/>
                    <measurement group_id="O2" value="40.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>15.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.11</ci_lower_limit>
            <ci_upper_limit>29.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate, Antepartum, of Hepatotoxicity, Defined by Protocol-specific Definition of Hepatotoxicity, Related to Treatment</title>
        <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. Protocol-specific definition of hepatotoxicity: Any one of the following: 1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 5 times the upper limit of normal (ULN), where ULN is specified by the clinic physician; 2) Total bilirubin &gt; 3 X ULN; 3) ALT greater than 3 X ULN and total bilirubin greater than 2 X ULN; or 4) ALT &gt; 3 X ULN and persistent symptomatic clinical hepatitis</description>
        <time_frame>Measured from study entry through delivery</time_frame>
        <population>All women enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate, Antepartum, of Hepatotoxicity, Defined by Protocol-specific Definition of Hepatotoxicity, Related to Treatment</title>
          <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. Protocol-specific definition of hepatotoxicity: Any one of the following: 1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 5 times the upper limit of normal (ULN), where ULN is specified by the clinic physician; 2) Total bilirubin &gt; 3 X ULN; 3) ALT greater than 3 X ULN and total bilirubin greater than 2 X ULN; or 4) ALT &gt; 3 X ULN and persistent symptomatic clinical hepatitis</description>
          <population>All women enrolled.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77"/>
                    <measurement group_id="O2" value="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.63</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate, to 12 Weeks Postpartum, of Hepatotoxicity, Protocol-specific Definition, Related to Treatment</title>
        <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata</description>
        <time_frame>Measured from study entry through 12 weeks postpartum</time_frame>
        <population>All women enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate, to 12 Weeks Postpartum, of Hepatotoxicity, Protocol-specific Definition, Related to Treatment</title>
          <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata</description>
          <population>All women enrolled.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91"/>
                    <measurement group_id="O2" value="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>3.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>8.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate, Antepartum, of Hepatotoxicity, Protocol-specific Definition, Any Cause</title>
        <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through delivery</time_frame>
        <population>All women enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate, Antepartum, of Hepatotoxicity, Protocol-specific Definition, Any Cause</title>
          <description>Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>All women enrolled.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77"/>
                    <measurement group_id="O2" value="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.63</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate, to 12 Weeks Postpartum, of Hepatotoxicity, Protocol-specific Definition, Any Cause</title>
        <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through 12 weeks postpartum</time_frame>
        <population>All women enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate, to 12 Weeks Postpartum, of Hepatotoxicity, Protocol-specific Definition, Any Cause</title>
          <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>All women enrolled</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.37"/>
                    <measurement group_id="O2" value="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>3.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>8.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate, Antepartum, of Hepatotoxicity, Defined by DAIDS, Related to Treatment</title>
        <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Hepatotoxicity definition as defined by DAIDS AE grading criteria 1.0.</description>
        <time_frame>Measured from study entry through delivery</time_frame>
        <population>All women.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate, Antepartum, of Hepatotoxicity, Defined by DAIDS, Related to Treatment</title>
          <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Hepatotoxicity definition as defined by DAIDS AE grading criteria 1.0.</description>
          <population>All women.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77"/>
                    <measurement group_id="O2" value="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.63</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate, up to 12 Weeks Postpartum, of Hepatotoxicity, Defined by DAIDS, Related to Treatment</title>
        <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata</description>
        <time_frame>Measured from study start through 12 weeks postpartum</time_frame>
        <population>All women</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate, up to 12 Weeks Postpartum, of Hepatotoxicity, Defined by DAIDS, Related to Treatment</title>
          <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata</description>
          <population>All women</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91"/>
                    <measurement group_id="O2" value="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>3.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>8.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate, Antepartum, of Hepatotoxicity, Defined by DAIDS, Any Cause</title>
        <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study entry through delivery</time_frame>
        <population>All women</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate, Antepartum, of Hepatotoxicity, Defined by DAIDS, Any Cause</title>
          <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>All women</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77"/>
                    <measurement group_id="O2" value="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.63</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate, up to 12 Weeks Postpartum, of Hepatotoxicity, Defined by DAIDS, Any Cause</title>
        <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
        <time_frame>Measured from study start through 12 weeks postpartum</time_frame>
        <population>All women.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate, up to 12 Weeks Postpartum, of Hepatotoxicity, Defined by DAIDS, Any Cause</title>
          <description>Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata.</description>
          <population>All women.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.37"/>
                    <measurement group_id="O2" value="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Incidence rate difference</param_type>
            <param_value>3.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>8.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Mothers With Tuberculosis Resistant to INH</title>
        <description>Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of mothers who develop culture-confirmed TB</description>
        <time_frame>Measured from study entry through Week 48 postpartum</time_frame>
        <population>Mothers with culture-confirmed TB</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Mothers With Tuberculosis Resistant to INH</title>
          <description>Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of mothers who develop culture-confirmed TB</description>
          <population>Mothers with culture-confirmed TB</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Tuberculosis Resistant to INH</title>
        <description>Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of infants who develop culture-confirmed TB</description>
        <time_frame>Measured from study entry through Week 48 after birth</time_frame>
        <population>No infants had culture-confirmed TB</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Tuberculosis Resistant to INH</title>
          <description>Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of infants who develop culture-confirmed TB</description>
          <population>No infants had culture-confirmed TB</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Parameter: Adjusted Mean of Area Under the Curve of Plasma Concentration Versus Time (AUC24h), for INH</title>
        <description>Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used,</description>
        <time_frame>Measured at antepartum (third trimester and &gt;= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.</time_frame>
        <population>Participants with intensive pharmacokinetic results while on active INH, who were established on INH.</population>
        <group_list>
          <group group_id="O1">
            <title>Fast Metabolizers</title>
            <description>Those women having a genotype of fast INH metabolism.</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers</title>
            <description>Those women having a genotype of intermediate INH metabolism.</description>
          </group>
          <group group_id="O3">
            <title>Slow Metabolizers</title>
            <description>Those women having a genotype of slow INH metabolism.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Adjusted Mean of Area Under the Curve of Plasma Concentration Versus Time (AUC24h), for INH</title>
          <description>Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used,</description>
          <population>Participants with intensive pharmacokinetic results while on active INH, who were established on INH.</population>
          <units>hour*mg/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Third trimester of pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" lower_limit="2.88" upper_limit="4.88"/>
                    <measurement group_id="O2" value="6.55" lower_limit="5.31" upper_limit="7.88"/>
                    <measurement group_id="O3" value="21.6" lower_limit="18.5" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 postpartum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" lower_limit="3.29" upper_limit="5.54"/>
                    <measurement group_id="O2" value="7.67" lower_limit="6.49" upper_limit="9.18"/>
                    <measurement group_id="O3" value="25.3" lower_limit="22.2" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Parameter: Adjusted Mean of Area Under the Curve (AUC24h), for EFV</title>
        <description>Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used,</description>
        <time_frame>Measured at antepartum (third trimester and &gt;= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.</time_frame>
        <population>Participants with intensive pharmacokinetic results while on active EFV and who were stabled on EFV-based ART.</population>
        <group_list>
          <group group_id="O1">
            <title>Fast Metabolizers</title>
            <description>Those women with a phenotype of fast EFV metabolism.</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Metabolizers</title>
            <description>Those women with a phenotype of intermediate EFV metabolism.</description>
          </group>
          <group group_id="O3">
            <title>Slow Metabolizers</title>
            <description>Those women with a phenotype of slow EFV metabolism.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Adjusted Mean of Area Under the Curve (AUC24h), for EFV</title>
          <description>Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used,</description>
          <population>Participants with intensive pharmacokinetic results while on active EFV and who were stabled on EFV-based ART.</population>
          <units>hour*mg/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Third trimester of pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="33.4" upper_limit="47.6"/>
                    <measurement group_id="O2" value="62.5" lower_limit="51.4" upper_limit="94.9"/>
                    <measurement group_id="O3" value="153.02" lower_limit="140.21" upper_limit="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 postpartum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="42.1" upper_limit="59.7"/>
                    <measurement group_id="O2" value="76.2" lower_limit="61.1" upper_limit="111"/>
                    <measurement group_id="O3" value="186" lower_limit="166" upper_limit="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Agreement Between Interferon-gamma Release Assay (IGRA) TB Test and Tuberculin Skin Test (TST) Results, Women at Delivery</title>
        <description>IGRA done by Quantiferon Gold Test (QGIT). For women, TST is considered positive if greater than or equal to 5 mm</description>
        <time_frame>Measured at delivery</time_frame>
        <population>Women tested for tuberculosis infection at delivery</population>
        <group_list>
          <group group_id="O1">
            <title>Positive IGRA TB Test</title>
            <description>Women who had positive IGRA TB test at delivery</description>
          </group>
          <group group_id="O2">
            <title>Negative IGRA TB Test</title>
            <description>Women who had negative IGRA TB test at delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Agreement Between Interferon-gamma Release Assay (IGRA) TB Test and Tuberculin Skin Test (TST) Results, Women at Delivery</title>
          <description>IGRA done by Quantiferon Gold Test (QGIT). For women, TST is considered positive if greater than or equal to 5 mm</description>
          <population>Women tested for tuberculosis infection at delivery</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="517"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive tuberculin skin test</title>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative tuberculin skin test</title>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Measuring agreement between the tests</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>McNemars test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Agreement between tests</non_inferiority_desc>
            <param_type>Kappa coefficient</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Agreement Between IGRA and TST TB Test Results, Infant</title>
        <description>The TST result was positive if greater than or equal to 10 mm in HIV-negative infants, or greater than or equal to 5 mm in HIV-positive infants.</description>
        <time_frame>Measured at week 44 after birth</time_frame>
        <population>Infants with tuberculin tests performed at week 44 postpartum</population>
        <group_list>
          <group group_id="O1">
            <title>Positive IGRA Test</title>
            <description>Infants with positive IGRA test at week 44 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Negative IGRA Tuberculin Test</title>
            <description>Infants with a negative IGRA test at 44 weeks postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Agreement Between IGRA and TST TB Test Results, Infant</title>
          <description>The TST result was positive if greater than or equal to 10 mm in HIV-negative infants, or greater than or equal to 5 mm in HIV-positive infants.</description>
          <population>Infants with tuberculin tests performed at week 44 postpartum</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="642"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive tuberculin skin test</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative tuberculin skin test</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Agreement between tests</non_inferiority_desc>
            <p_value>0.22</p_value>
            <method>Chi-squared</method>
            <method_desc>McNemar's test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Agreement between tests</non_inferiority_desc>
            <param_type>Kappa coefficient</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Agreement Between IGRA and TST TB Tests, Women at 44 Weeks Postpartum</title>
        <description>IGRA done by Quantiferon Gold Test (QGIT). For women, TST is considered positive if greater than or equal to 5 mm</description>
        <time_frame>Measured at Week 44 postpartum</time_frame>
        <population>Women who were tested for tuberculosis infection at 44 weeks postpartum</population>
        <group_list>
          <group group_id="O1">
            <title>Positive IGRA TB Test</title>
            <description>Women who had positive IGRA TB test at 44 weeks postpartum</description>
          </group>
          <group group_id="O2">
            <title>Negative IGRA TB Test</title>
            <description>Women who had negative IGRA TB test at 44 weeks postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Agreement Between IGRA and TST TB Tests, Women at 44 Weeks Postpartum</title>
          <description>IGRA done by Quantiferon Gold Test (QGIT). For women, TST is considered positive if greater than or equal to 5 mm</description>
          <population>Women who were tested for tuberculosis infection at 44 weeks postpartum</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive tuberculin skin test</title>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative tuberculin skin test</title>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Agreement between tests</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>McNemar's test</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Agreement between tests</non_inferiority_desc>
            <param_type>Kappa coefficient</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Women by Level of Adherence to Prescribed Regimen, as Assessed by Self-report</title>
        <description>Adherence is the percentage of expected doses taken during the 28 week active treatment period, categorized as poor (&lt;60%), reasonable (&gt;= 60%, &lt;80%), good (&gt;=80%, &lt;90%), or excellent (&gt;= 90%). Measured by participant's self-report of doses taken within the last 3 days.</description>
        <time_frame>Adherence reported every 4 weeks during active treatment; study entry through week 28 for Arm A, week 12 postpartum through week 40 postpartum for Arm B</time_frame>
        <population>All women enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Women by Level of Adherence to Prescribed Regimen, as Assessed by Self-report</title>
          <description>Adherence is the percentage of expected doses taken during the 28 week active treatment period, categorized as poor (&lt;60%), reasonable (&gt;= 60%, &lt;80%), good (&gt;=80%, &lt;90%), or excellent (&gt;= 90%). Measured by participant's self-report of doses taken within the last 3 days.</description>
          <population>All women enrolled.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Excellent adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                    <measurement group_id="O2" value="363"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Reasonable adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Women by Level of Adherence to Prescribed Regimen, as Assessed by Pill Count</title>
        <description>Adherence is the percentage of expected doses taken during the 28 week active treatment period. Pill count: participants returned their prescription pill containers, and the remaining (unused) pills were counted.</description>
        <time_frame>Adherence reported every 4 weeks during active treatment; study entry through week 28 for Arm A, week 12 postpartum through week 40 postpartum for Arm B</time_frame>
        <population>All enrolled women</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Immediate INH Treatment)</title>
            <description>Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Deferred INH Treatment)</title>
            <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from Week 12 postpartum through Week 40 postpartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Women by Level of Adherence to Prescribed Regimen, as Assessed by Pill Count</title>
          <description>Adherence is the percentage of expected doses taken during the 28 week active treatment period. Pill count: participants returned their prescription pill containers, and the remaining (unused) pills were counted.</description>
          <population>All enrolled women</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Excellent adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="408"/>
                    <measurement group_id="O2" value="376"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Reasonable adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study entry to study completion at week 48 postpartum or premature study discontinuation</time_frame>
      <desc>At entry, all diagnoses, signs/symptoms, and laboratory events were collected. Post-entry, all new diagnoses, signs/symptoms, or laboratory events of &gt;= 3 and all signs/symptoms and laboratory events that led to a change in treatment, regardless of grade, were collected. The DAIDS AE Grading Table (V1.0) and EAE Manual (V2.0) were used. All eligible participants who initiated study treatment and their live-born infants are included.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mother/Immediate INH</title>
          <description>Women in Arm A received immediate, or antepartum-initiated, INH treatments. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by mouth, from entry through Week 28 antepartum
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from Week 28 visit through Week 40 postpartum.</description>
        </group>
        <group group_id="E2">
          <title>Mother/Deferred INH</title>
          <description>Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
Isoniazid (INH): 300-mg tablet once daily by month, from Week 12 postpartum through Week 40 postpartum.
Placebo for isoniazid (INH): Placebo tablet once daily by mouth, from entry until Week 12 postpartum visit.</description>
        </group>
        <group group_id="E3">
          <title>Infant/Immediate INH</title>
          <description>Infants born alive to mothers on arm A (Immediate INH).</description>
        </group>
        <group group_id="E4">
          <title>Infant/Deferred INH</title>
          <description>Infants born alive to mothers on Arm B (Deferred INH).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="91" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Anaemia neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemorrhagic disease of newborn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Choledochal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Congenital cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Congenital hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Congenital pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Congenital syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dysmorphism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Exomphalos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Fever neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Macrosomia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Rhesus incompatibility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cryptosporidiosis infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemophilus sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Parvovirus B19 infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Postpartum sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Adverse event following immunisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Anal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Foreign body in respiratory tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Induced abortion failed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Uterine rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Symphysiolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hypocalcaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>False labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Foetal growth restriction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Foetal hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemorrhage in pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Low birth weight baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Meconium stain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Peripartum cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Placenta praevia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Preterm premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Prolonged rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Small for dates baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Uterine inversion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine atony</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Meconium aspiration syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Transient tachypnoea of the newborn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="438" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="449" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="417" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="430" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="353" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="365" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="270" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="264" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Growth failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melissa Allen, Director, IMPAACT Operations Center</name_or_title>
      <organization>Family Health International (FHI 360)</organization>
      <phone>(919) 405-1429</phone>
      <email>mallen@fhi360.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

